Redeye saw sales development that was far better than our expectations. Sales development compared to last year’s quarter was up 46%. Management's increased focus on the right deals has started to pay off. We have significantly increased our sales estimates for 2025/2026e while increasing costs to sustain the higher growth. We have increased our Base case to SEK 8.0 (6.7) per share and our Fair value range to SEK 3.9 – 16.2 (3.6–15) per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/